Internists most likely to switch patients off Avandia
July 17 2007
Though the FDA has yet to advise on the cardiovascular safety of GlaxoSmithKlines Avandia type 2 diabetes drug, some physicians ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.